Search

Your search keyword '"Bernadach M"' showing total 23 results
Start Over Author "Bernadach M"
23 results on '"Bernadach M"'

1. Beneath HMGA2 alterations in pleomorphic adenomas: Pathological, immunohistochemical, and molecular insights

Author

Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Grayeli, A.Bozorg, Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Clatot, F., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F.R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Saint Guily, J. Lacau, Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Cardon, A.Lasne, Le Tourneau, C., Lefebvre, G., Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A., Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Dang, N. Pham, Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., J.-M.Prades, Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Siegfried, A., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., J.Thariat, David, M. Timar, Timochenko, A., Toussaint, B., Coste, E. Uro, Valette, G., Van den Abbele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., Wong, S., Alsugair, Ziyad, Lépine, Charles, Descotes, Françoise, Lanic, Marie-Delphine, Pissaloux, Daniel, Tirode, Franck, Lopez, Jonathan, Céruse, Philippe, Philouze, Pierre, Fieux, Maxime, Wassef, Michel, Baglin, Anne-Catherine, Mihaela, Onea, Castain, Claire, Sudaka, Anne, Uro-Coste, Emmanuelle, Champagnac, Anne, Costes-Martineau, Valérie, Laé, Marick, and Benzerdjeb, Nazim

Published
2024
Full Text
View/download PDF

2. Characterization of a Molecularly Distinct Subset of Oncocytic Pleomorphic Adenomas/Myoepitheliomas Harboring Recurrent ZBTB47-AS1: PLAG1 Gene Fusion

Author

Alsugair, Ziyad, Perrot, Jimmy, Descotes, Françoise, Lopez, Jonathan, Champagnac, Anne, Pissaloux, Daniel, Castain, Claire, Onea, Mihaela, Céruse, Philippe, Philouze, Pierre, Lépine, Charles, Lanic, Marie-Delphine, Laé, Marick, Costes-Martineau, Valérie, Benzerdjeb, Nazim, Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Grayeli, A. Bozorg, Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Clatot, F., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F. R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Saint Guily, J. Lacau, Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Cardon, A. Lasne, Le Tourneau, C., Lefebvre, G, Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A, Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Dang, N. Pham, Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., Prades, J.-M., Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., Thariat, J., David, M. Timar, Timochenko, A., Toussaint, B., Coste, E. Uro, Valette, G., Van den Abbele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., and Wong, S.

Published
2024
Full Text
View/download PDF

3. Impact of facial nerve resection in parotid cancer abutting the facial nerve without preoperative paralysis: A multicentric propensity score-based analysis

Author

Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Bettoni, J., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Bozorg Grayeli, A., Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Classe, M., Clatot, F., Colin, E., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Espitalier, F., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F.R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Lacau Saint Guily, J., Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Lasne Cardon, A., Le Tourneau, C., Lefebvre, G., Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A., Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Pham Dang, N., Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., Prades, J.-M., Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., Thariat, J., Timar David, M., Timochenko, A., Toussaint, B., Uro Coste, E., Valette, G., Van den Abbeele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., Wong, S., Chatelet, Florian, Chevret, Sylvie, Fakhry, Nicolas, Even, Caroline, Malard, Olivier, de Monès, Erwan, Saroul, Nicolas, Mouawad, François, de Boutray, Marie, Mauvais, Olivier, Vergez, Sébastien, Evrard, Diane, Righini, Christian, Schultz, Philippe, Baudouin, Robin, Poissonnet, Gilles, Atallah, Sarah, Haroun, Fabienne, Morinière, Sylvain, Evrard, Camille, Philouze, Pierre, Paasche, Agnès, Lesnik, Maria, Lelonge, Yann, Herman, Philippe, and Verillaud, Benjamin

Published
2024
Full Text
View/download PDF

6. Characterization of a Molecularly Distinct Subset of Oncocytic Pleomorphic Adenomas/Myoepitheliomas Harboring Recurrent ZBTB47-AS1::PLAG1Gene Fusion

Author

Alsugair, Ziyad, Perrot, Jimmy, Descotes, Françoise, Lopez, Jonathan, Champagnac, Anne, Pissaloux, Daniel, Castain, Claire, Onea, Mihaela, Céruse, Philippe, Philouze, Pierre, Lépine, Charles, Lanic, Marie-Delphine, Laé, Marick, Costes-Martineau, Valérie, Benzerdjeb, Nazim, Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Grayeli, A. Bozorg, Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Clatot, F., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F. R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Saint Guily, J. Lacau, Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Cardon, A. Lasne, Le Tourneau, C., Lefebvre, G, Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A, Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Dang, N. Pham, Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., Prades, J.-M., Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., Thariat, J., David, M. Timar, Timochenko, A., Toussaint, B., Coste, E. Uro, Valette, G., Van den Abbele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., and Wong, S.

Abstract

Recurrent gene fusions are common in salivary gland tumors including benign tumors, such as pleomorphic adenoma (PA) and myoepithelioma (ME). In cases where chromosomal rearrangement is identified in the pleomorphic adenoma gene 1 (PLAG1)gene, different gene partners are found. Oncocytic metaplasia, characterized by oncocytes with abundant eosinophilic granular cytoplasm and hyperchromatic nuclei, is a well-known phenomenon in salivary gland neoplasms. However, the pure oncocytic variant of PA/ME showed PLAG1gene rearrangements involving various gene partners at the molecular level, without any recurrent fusion being found. Our study includes 20 cases of PA/ME, with 11 females and 9 males. The age of patients ranged from 37 to 96 years, with a median age of 62.8 years. Most tumors originate from the parotid gland. The median size of the tumor was 26.5 mm (range: 13 to 60 mm). Among the 20 cases, 14 were a pure oncocytic variant of PA/ME, whereas 6 cases showed focal oncocytic or oncocytic-like aspects. Molecular studies on 20 cases of PA/ME were conducted. A novel recurrent ZBTB47-AS1::PLAG1fusion was identified in 6 of 12 cases with pure oncocytic metaplasia, whereas the other cases had PLAG1gene fusion with different gene partners. The transcriptomic analysis of the cases harboring ZBTB47-AS1::PLAG1fusion demonstrated that these tumors have a distinct molecular profile from conventional PA/ME. This study reveals a unique subset in the oncocytic PA/ME spectrum characterized by pure oncocytic morphology with larger oncocytic cells and recurrent ZBTB47-AS1::PLAG1fusion. It also highlights the transcriptomic distinctness of salivary gland adenomas with pure oncocytic metaplasia in the spectrum of salivary gland neoplasms. Further studies are needed to better understand the oncocytic variant of PA/ME and to determine the true nature of oncocytic cells in PA/ME.

Published
2024
Full Text
View/download PDF

7. [Impact of HPV status on nutritional status during radio chemotherapy for oropharyngeal cancer]

Author

Saroul, N., Martraix, C., Mulliez, A., Cassagnes, L., Puechmaille, M., Bernadach, M., Biau, J., Walrand, S., Lapeyre, M., Imagerie Moléculaire et Stratégies Théranostiques (IMoST), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)

Subjects
HPV, Oropharyngeal cancer, Cancer de l’oropharynx, Radiotherapy, NRI, [SDV.CAN]Life Sciences [q-bio]/Cancer, SIRI, Nutrition, Radiothérapie
Abstract

Patients with oropharyngeal cancer are at high nutritional risk before and during treatment. Little is known about the influence of human papillomavirus (HPV) infection on nutritional status and its evolution during treatment.A single-center retrospective study was conducted between August 2017 and December 2020 including 48 patients (14 HPV-induced: HPV+ and 34 non-HPV-induced: HPV-) with oropharyngeal squamous cell carcinoma treated by radiotherapy±chemotherapy (RT/CT). Nutritional risk at the time of tumor assessment (TA) was assessed by weight loss, swallowing ability, and the presence of digestive disorders in 4 stages of increasing severity. Nutritional status was assessed by weight and nutrition risk index (NRI) at the time of TA, before the start and at 3 months from the end of RT±CT. During RT±CT, the NRI and the systemic inflammatory response index (SIRI=neutrophils * monocytes/lymphocytes) were assessed weekly.HPV+patients were at lower nutritional risk at TA (50% grade ≥2 vs 85%, P=0.02), lost more weight (6% of their body weight vs 3%, P=0.05), and increased their SIRI by 7.5 points more than HPV- patients (P=0.04) during RT/CT.HPV+ oropharyngeal cancer patients are at high nutritional risk even in the absence of undernutrition at the outset of management.

Published
2022
Full Text
View/download PDF

8. Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second‐line docetaxel: A randomized trial

Author

Passildas Jahanmohan Judith, Bernadach Maureen, Pouget Mélanie, Kwiatkowski Fabrice, Vanpraagh‐Doreau Isabelle, Dubray‐Longeras Pascale, Abrial Catherine, Nabholtz Jean‐Marc, Curé Hervé, Delecroix Valérie, Chollet Philippe, and Mouret‐Reynier Marie‐Ange

Subjects
advanced and metastatic breast cancer, chemotherapy, curcumin, docetaxel, phytotherapy, Medicine
Abstract

Abstract Background In this study, we investigated whether the association of curcumin and docetaxel among advanced and metastatic breast cancer patients in first or second‐line treatment potentiated the objective response rate. Patients/Methods A multicentre, randomized, open label, phase‐II study was conducted and included 42 patients from July 2009 to January 2017. The primary endpoint was the objective response rate of the docetaxel‐curcumin combination in comparison with docetaxel alone. The secondary endpoints were the assessment of clinical benefit, overall survival, time‐to‐progression, progression‐free survival, compliance, and safety. An interim analysis was planned to evaluate safety and efficacy. Results In this interim analysis conducted on 37 patients (19 in the control group vs. 18 in the experimental group), no difference was observed for the objective response rate (p = 0.25, control 73.7% vs. experimental 55.6%). Concerning clinical benefit, overall survival and time‐to‐progression, we also failed to show any difference between the two arms. A slight tendency towards longer progression‐free survival at 12 months after randomization was observed in the curcumin group (65.5% vs. 41.4%) but this difference did not reach significance (p = 0.14). Conclusion In this study, we showed for the first time that adding oral curcumin for advanced and metastatic breast cancer patients treated with first or second‐line docetaxel was not efficacious, although safe. Consequently, this study was stopped for reasons of futility. Further studies with a larger number of patients, a different curcumin preparation, a longer treatment period and a pharmacokinetic evaluation of curcumin are needed to explore the real efficacy of this compound.

Published
2024
Full Text
View/download PDF

9. 81P Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase II trial

Author

Fayette, J., primary, Bauman, J., additional, Salas, S., additional, Colevas, D., additional, Even, C., additional, Cupissol, D., additional, Posner, M.R., additional, Lefebvre, G., additional, Saada-Bouzid, E., additional, Bernadach, M., additional, Seiwert, T., additional, Pearson, A., additional, Messouak, S., additional, Cornen, S.L., additional, Andre, P., additional, Rotolo, F., additional, Boyer-Chammard, A., additional, and Cohen, R.B., additional

Published
2020
Full Text
View/download PDF

10. Comparison of the Predictive and Prognostic Capacities of Neutrophil, Lymphocyte and Platelet Counts and Tumor-infiltrating Lymphocytes in Triple-negative Breast Cancer: Preliminary Results of the PERCEPTION Study.

Author

Giro A, Passildas-Jahanmohan J, Kossai M, Bidet Y, Molnar I, Bernadach M, Penault-Llorca F, Abrial C, Durando X, and Radosevic-Robin N

Subjects
Humans, Female, Prognosis, Middle Aged, Platelet Count, Aged, Adult, Lymphocytes immunology, Lymphocytes metabolism, Lymphocyte Count, Biomarkers, Tumor blood, Blood Platelets metabolism, Blood Platelets pathology, Blood Platelets immunology, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Triple Negative Breast Neoplasms immunology, Triple Negative Breast Neoplasms pathology, Triple Negative Breast Neoplasms blood, Neutrophils immunology, Neutrophils pathology, Neutrophils metabolism
Abstract

Background/aim: Triple-negative breast cancer (TNBC) is the most heterogeneous breast cancer subtype, posing numerous challenges in clinical decision-making. Biomarkers are essential to personalize management of TNBC patients. While tumor infiltrating lymphocytes (TILs) are validated prognostic biomarkers, the requirement for tumor biopsy limits their routine use. Therefore, more accessible and reliable quantitative biomarkers are needed. Given the significant role of systemic inflammatory response in tumor onset and progression, assessing inflammatory cells via liquid biopsies emerges as a promising alternative., Patients and Methods: The PERCEPTION study, conducted at Centre Jean Perrin in France, aims to determine the correlation between TILs and peripheral blood components at diagnosis. An interim analysis was conducted after enrolling 50% of the estimated population, to evaluate study feasibility and preliminary correlations between blood cell counts and TILs., Results: Sixty-one patients were enrolled over 4.5 years, demonstrating a good inclusion rate with minimal missing data. Preliminary results for 36 analyzable patients showed no correlation between the neutrophil-to-lymphocyte ratio (NLR) and TILs (r s =-0.19, 95%CI=-0.49-0.16, p=0.3). However, a moderate, positive, statistically significant correlation was found between NLR and the CD8/FoxP3 TILs ratio (r s =0.36, 95%CI=0.03-0.64, p=0.043). The probabilistic index of 0.7 (p=0.06) between NLR-high and NLR-low groups for this ratio supports the correlation., Conclusion: The interim analysis of the PERCEPTION study confirms the feasibility of correlating blood cell counts with TILs in TNBC. Although no significant correlation was observed between NLR and TILs, the moderate positive correlation between the CD8/FoxP3 ratio and TILs suggests a potential link between systemic inflammation and local immune response. These findings underscore the potential of blood-based markers as non-invasive surrogates for TILs, encouraging further research to enhance prognosis and guide treatment strategies in TNBC., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2024
Full Text
View/download PDF

11. The efficacy of immune checkpoint inhibitors following discontinuation for long-term response or toxicity in advanced or metastatic non-small-cell lung cancers: A retrospective study.

Author

Vacher L, Bernadach M, Molnar I, Passildas-Jahanmohan J, and Dubray-Longeras P

Abstract

Background and Aims: The treatment of metastatic non-small-cell lung cancer (NSCLC) has been revolutionized by the arrival of immune checkpoint inhibitors (ICI). For patients without immune related adverse events (irAEs), it is recommended to continue the treatment as long as it provides clinical benefit or until unacceptable toxicity appears. The aim of our study was to evaluate survival data among patients with advanced or metastatic NSCLC following ICI discontinuation for reasons of long-term response or toxicity (irAEs)., Methods: We included all patients with advanced or metastatic NSCLC treated with nivolumab and pembrolizumab at the Centre Jean Perrin, Clermont-Ferrand, France (January 1, 2016 to May 31, 2019). We focused on two groups in this study population: "Voluntary treatment discontinuation" (medical decision as a result of long-term response and patient decision) and "Treatment discontinuation due to toxicity" (irAEs). The primary endpoint was to evaluate the postdiscontinuation outcomes of these two groups: progression-free survival (PFS) and overall survival (OS), and rechallenge in the "voluntary discontinuation" group., Results: The final analysis concerned 146 patients, including 10 (7%) in the "discontinuation due to toxicity" group, 11 (8%) in the "voluntary discontinuation" group, 100 (68%) who discontinued treatment as a result of progression and 25 (17%) whose treatment was still on-going. The median PFS in the "discontinuation due to toxicity" group was not reached, and in the "voluntary discontinuation" group ( n  = 11) was 37 months ( p  = 0.4), versus 2 months in the progression group ( p  < 0.001). The median OS in "discontinuation due to toxicity," and in the "voluntary discontinuation" groups was not reached ( p  = 0.5), versus 10 months in the progression group ( p  < 0.001)., Conclusion: Treatment discontinuation following long-term response to ICI treatment showed sustained response and long-term survival after discontinuation. The incidence of irAEs was associated with better long-term survival, even after ICI discontinuation., Competing Interests: The authors declare no conflict of interest., (© 2024 The Authors. Health Science Reports published by Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

12. Outcomes among oropharyngeal and oral cavity cancer patients treated with postoperative volumetric modulated arctherapy.

Author

Mione C, Casile M, Moreau J, Miroir J, Molnar I, Chautard E, Bernadach M, Kossai M, Saroul N, Martin F, Pham-Dang N, Lapeyre M, and Biau J

Abstract

Background: Presently, there are few published reports on postoperative radiation therapy for oropharyngeal and oral cavity cancers treated with IMRT/VMAT technique. This study aimed to assess the oncological outcomes of this population treated with postoperative VMAT in our institution, with a focus on loco-regional patterns of failure., Material and Methods: Between 2011 and 2019, 167 patients were included (40% of oropharyngeal cancers, and 60% of oral cavity cancers). The median age was 60 years. There was 64.2% of stage IV cancers. All patients had both T and N surgery. 34% had a R1 margin, 42% had perineural invasion. 72% had a positive neck dissection and 42% extranodal extension (ENE). All patients were treated with VMAT with simultaneous integrated boost with three dose levels: 66Gy in case of R1 margin and/or ENE, 59.4-60Gy on the tumor bed, and 54Gy on the prophylactic areas. Concomittant cisplatin was administrated concomitantly when feasible in case of R1 and/or ENE., Results: The 1- and 2-year loco-regional control rates were 88.6% and 85.6% respectively. Higher tumor stage (T3/T4), the presence of PNI, and time from surgery >45 days were significant predictive factors of worse loco-regional control in multivariate analysis (p=0.02, p=0.04, and p=0.02). There were 17 local recurrences: 11 (64%) were considered as infield, 4 (24%) as marginal, and 2 (12%) as outfield. There were 9 regional recurrences only, 8 (89%) were considered as infield, and 1 (11%) as outfield. The 1- and 2-year disease-free survival (DFS) rates were 78.9% and 71.8% respectively. The 1- and 2-year overall survival (OS) rates were 88.6% and 80% respectively. Higher tumor stage (T3/T4) and the presence of ENE were the two prognostic factors significantly associated with worse DFS and OS in multivariate analysis., Conclusion: Our outcomes for postoperative VMAT for oral cavity and oropharyngeal cancers are encouraging, with high rates of loco-regional control. However, the management of ENE still seems challenging., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Mione, Casile, Moreau, Miroir, Molnar, Chautard, Bernadach, Kossai, Saroul, Martin, Pham-Dang, Lapeyre and Biau.)

Published
2023
Full Text
View/download PDF

13. Prediction of residual disease using circulating DNA detection after potentiated radiotherapy for locally advanced head and neck cancer (NeckTAR): a study protocol for a prospective, multicentre trial.

Author

Ginzac A, Ferreira MC, Cayre A, Bouvet C, Biau J, Molnar I, Saroul N, Pham-Dang N, Durando X, and Bernadach M

Subjects
Humans, DNA, Complementary, Multicenter Studies as Topic, Positron Emission Tomography Computed Tomography, Prospective Studies, Carcinoma, Squamous Cell pathology, Cell-Free Nucleic Acids, Head and Neck Neoplasms genetics, Head and Neck Neoplasms radiotherapy
Abstract

Background: Sensitive and reproducible detection of residual disease after treatment is a major challenge for patients with locally advanced head and neck cancer. Indeed, the current imaging techniques are not always reliable enough to determine the presence of residual disease. The aim of the NeckTAR trial is to assess the ability of circulating DNA (cDNA), both tumoral and viral, at three months post-treatment, to predict residual disease, at the time of the neck dissection, among patients with partial cervical lymph node response on PET-CT, after potentiated radiotherapy., Methods: This will be an interventional, multicentre, single-arm, open-label, prospective study. A blood sample will be screened for cDNA before potentiated radiotherapy and after 3 months if adenomegaly persists on the CT scan 3 months after the end of treatment. Patients will be enrolled in 4 sites in France. Evaluable patients, i.e. those with presence of cDNA at inclusion, an indication for neck dissection, and a blood sample at M3, will be followed for 30 months. Thirty-two evaluable patients are expected to be recruited in the study., Discussion: The decision to perform neck dissection in case of persistent cervical adenopathy after radio-chemotherapy for locally advanced head and neck cancer is not always straightforward. Although studies have shown that circulating tumour DNA is detectable in a large proportion of patients with head and neck cancer, enabling the monitoring of response, the current data is insufficient to allow routine use of this marker. Our study could lead to better identification of patients who do not have residual lymph node disease in order to avoid neck dissection and preserve their quality-of-life while maintaining their prospects of survival., Trial Registration: Clinicaltrials.gov: NCT05710679, registered on 02/02/2023, https://clinicaltrials.gov/ct2/show/ . Identifier with the French National Agency for the Safety of Medicines and Health Products (ANSM): N°ID RCB 2022-A01668-35, registered on July 15 th , 2022., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

14. Toxicity of induction chemotherapy in head and neck cancer: The central role of skeletal muscle mass.

Author

Lere-Chevaleyre A, Bernadach M, Lambert C, Cassagnes L, Puechmaille M, Mom T, Gilain L, Lapeyre M, Boirie Y, Biau J, and Saroul N

Subjects
Antineoplastic Combined Chemotherapy Protocols adverse effects, Cisplatin adverse effects, Docetaxel, Fluorouracil adverse effects, Humans, Muscle, Skeletal diagnostic imaging, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms etiology, Induction Chemotherapy adverse effects
Abstract

Background: To assess the impact of nutritional status on tolerance to induction chemotherapy by docetaxel, cisplatin and 5-fluorouracil (ICT) in head and neck cancer (HNC)., Methods: Ninety-two HNC patients were included. Toxicity was assessed according to common terminology criteria for adverse events. Nutritional status was assessed by body mass index (BMI), serum albumin, nutritional risk index (NRI), and CT scan (skeletal muscle mass index [SMI] at the first lumbar vertebral level)., Results: Before treatment, average BMI was 22.7 ± 4.6 kg/m 2 , serum albumin 38.7 ± 5.8 g/L, NRI 97.6 ± 10.6, and SMI 36.4 ± 7.9 cm 2 /m 2 . After treatment, BMI was 23 ± 4.5, serum albumin 30.2 ± 7.1, and NRI 88.1 ± 9.2. During ICT, 52 (62%) patients developed at least one toxicity ≥ Grade 3. Pre-treatment SMI was the only predictive factor of toxicity irrespective of BMI (p = 0.04)., Conclusion: Low skeletal muscle mass is a predictive factor of toxicity to ICT in HNC., (© 2021 Wiley Periodicals LLC.)

Published
2022
Full Text
View/download PDF

15. Prognosis in Head and Neck Cancer: Importance of Nutritional and Biological Inflammatory Status.

Author

Saroul N, Puechmaille M, Lambert C, Hassan AS, Biau J, Lapeyre M, Mom T, Bernadach M, and Gilain L

Subjects
Aged, Female, Head and Neck Neoplasms blood, Humans, Lymphocyte Count, Male, Middle Aged, Monocytes, Neutrophils, Platelet Count, Prognosis, Retrospective Studies, Survival Rate, Head and Neck Neoplasms diagnosis, Head and Neck Neoplasms epidemiology, Inflammation complications, Nutritional Status, Social Status
Abstract

Objectives: To determine the importance of nutritional status, social status, and inflammatory status in the prognosis of head and neck cancer., Study Design: Single-center retrospective study of prospectively collected data., Setting: Tertiary referral center., Methods: Ninety-two consecutive patients newly diagnosed for cancer of the upper aerodigestive tract without metastases were assessed at time of diagnosis for several prognostic factors. Nutritional status was assessed by the nutritional risk index, social status by the EPICES score, and inflammatory status by the systemic inflammatory response index. The primary endpoint was overall survival., Results: In multivariable analysis, the main prognostic factors were the TNM classification (hazard ratio [HR] = 3.34, P = .002, for stage T3-4), malnutrition as assessed by the nutritional risk index (HR = 3.64, P = .008, for severe malnutrition), and a systemic inflammatory response index score ≥1.6 (HR = 3.32, P = .02). Social deprivation was not a prognostic factor., Conclusion: Prognosis in head and neck cancer is multifactorial; however, malnutrition and inflammation are important factors that are potentially reversible by early intervention.

Published
2022
Full Text
View/download PDF

16. Adapted Physical Activity for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Trastuzumab Against HER2 (APACAN2): A Protocol for a Feasibility Study.

Author

Ginzac A, Bernadach M, Molnar I, Duclos M, Thivat E, and Durando X

Abstract

Background: The standard care for HER2-positive breast cancer is chemotherapy plus a HER2-directed therapy. This can lead to treatment-induced cardiotoxicity. On the other hand, the practice of physical activity is known to improve cardiac function; thus HER2-positive breast cancer patients could draw particular benefit from physical activity during treatment. However, at the time of diagnosis for breast cancer, the majority of patients are insufficiently active according to physical activity recommendations of World Health Organisation, and it is difficult to remain or become active during the treatment. There is a lack of data in the literature on the optimal program to propose to patients to encourage them to be active during treatment. The aim of our study is to assess the feasibility of a home-based physical activity program during neoadjuvant chemotherapy and trastuzumab for HER2-positive breast cancer., Methods: The APACAN2 study is a single-centre, non-randomized interventional trial. Patients with HER2-positive breast cancer treated with anthracycline-based neoadjuvant chemotherapy and trastuzumab are eligible for enrolment. The supervised home-based physical activity program takes place during neoadjuvant chemotherapy (NACT). It combines aerobic and strengthening exercises. The primary endpoint is the proportion of patients reaching the international physical activity recommendations, i.e. 150 minutes of moderate-intensity activity per week at the end of NACT. The study started in April 2018 and seventy patients are expected to be recruited., Discussion: In the literature, the majority of studies on practice of physical activity in breast cancer focus on adjuvant chemotherapy or on the period after the end of treatment. To the best of our knowledge, the APACAN2 study is the first to evaluate a home-based physical activity program during neoadjuvant chemotherapy for HER2-positive breast cancer., Trial Registration Number: Clinicaltrials.gov: NCT02963363, registered on July 11, 2016. Identifier with the French National Agency for the Safety of Medicines and Health Products N°ID RCB 2016-A01344-47, registered in August 2016. Protocol: version 8, 24 February 2021., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Ginzac, Bernadach, Molnar, Duclos, Thivat and Durando.)

Published
2021
Full Text
View/download PDF

17. Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report.

Author

Leyrat B, Durando X, Veyssiere H, and Bernadach M

Abstract

Background: For patients with non-epidermal non-small-cell lung cancer (NSCLC), molecular alterations should always be investigated, especially in non-smokers, who have a very high frequency of targetable alterations (EGFR 52%; ALK 8% in particular). MET exon 14 alterations are identified in 3-4% of NSCLCs and MET gene amplification and high protein expression are associated with a poor prognosis. The French recommendations only authorize the use of capmatinib and crizotinib if the mutation concerns exon 14. However, several different types of mutation in exon 14 of MET and its flanking introns can induce a jump in exon 14, activate the MET gene and thus be sensitive to anti-MET tyrosine kinase inhibitors., Case Summary: This case concerns a 76-year-old Caucasian male with a medical history including idiopathic thrombocytopenic purpura, chronic myelomonocytic leukemia (CMML), atrial fibrillation, arterial hypertension, obesity (BMI 36kg/m2), and a 5-10 pack-per-year smoking history. A left upper lobe pulmonary nodule of 12.4 mm was discovered in March 2019. The patient received adjuvant chemotherapy with carboplatin AUC 5 and vinorelbine 25.00 mg/m2. At the end of the adjuvant treatment, the patient was in complete remission for 5 months. In February 2020, the CT scan revealed a mediastinal lymph node progression. A complementary molecular analysis was realized on the initial surgical specimen. A c.3082+3A>T mutation in the MET gene was identified. This mutation confers susceptibility to anti-MET tyrosine kinase inhibitors. Treatment with crizotinib was initiated with an initial dose of 250 mg/day for 15 days and then increased to 250 mg twice a day. After 7 months of treatment with crizotinib, the disease was still stable according to RECIST 1.1., Conclusion: We report here the original case of a patient presenting a lung adenocarcinoma with an intron 14 mutation and having a durable TKI response., Competing Interests: The authors report no conflicts of interest in this work., (© 2021 Leyrat et al.)

Published
2021
Full Text
View/download PDF

18. INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer.

Author

Veyssière H, Lusho S, Molnar I, Kossai M, Bernadach M, Abrial C, Bidet Y, Radosevic-Robin N, and Durando X

Abstract

Background: Triple negative breast cancer (TNBC) accounts for 10-20% of breast cancers but has no specific therapy. While TNBC may be more sensitive to chemotherapy than other types of breast cancer, it has a poor prognosis. Most TNBC relapses occur during the five years following treatment, however predictive biomarkers of metastatic relapse are still lacking. High tumour-infiltrating lymphocytes (TILs) levels before and after neo-adjuvant chemotherapy (NAC) are associated with lower relapse risk and longer survival but TILs assessment is highly error-prone and still not introduced into the clinic. Therefore, having reliable biomarker of relapse, but easier to assess, remains essential for TNBC management. Searching for such biomarkers among serum/plasma proteins, circulating tumoral DNA (ctDNA) and blood cells appear relevant., Methods: This single-centre and prospective study aims to discover predictive biomarkers of TNBC relapse and particularly focuses on plasma proteins. Blood samples will be taken at diagnosis, on the day of first-line or post-NAC surgery, on the day of radiotherapy start, then 6 months and one year after radiotherapy. A blood sample will be taken at the time of metastatic relapse diagnosis. Blood samples will be used for circulating protein quantification, blood cell counts and circulating tumour DNA quantification. A tumour RNA signature, based on the analysis of the RNA expression of 6 genes, will also be tested from the initial biopsy taken routinely. In NAC patients, TILs quantity will be assessed on TNBC pre-treatment biopsy and surgical specimen., Ethics and Dissemination: INSTIGO belongs to category 2 interventional research on humans. This study has been approved by the SUD - EST IV ethics committee and is conducted in accordance with the Declaration of Helsinki and General Data Protection Regulation (GDPR). Study findings will be published in peer-reviewed medical journals., Clinical Trial Registration: ClinicalTrials.gov, identifier NCT04438681., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Veyssière, Lusho, Molnar, Kossai, Bernadach, Abrial, Bidet, Radosevic-Robin and Durando.)

Published
2021
Full Text
View/download PDF

19. Sister Mary Joseph Nodules: A Case Report about a Rare Location of Skin Metastasis.

Author

Leyrat B, Bernadach M, Ginzac A, Lusho S, and Durando X

Abstract

Umbilical skin metastases (or Sister Mary Joseph nodules) are rare. Their presence typically indicates the late manifestation of deep-seated abdominopelvic malignancy. They occur mainly in gynecological cancers, and gastrointestinal cancers in men. The most common histology is adenocarcinoma (∼75% of cases), but it can also rarely be squamous cell or undifferentiated carcinoma. These metastases can be present at diagnosis or appear at disease recurrence, and are associated with a very poor prognosis with an average survival of 11 months. We report the clinical case of a 58-year-old man with metastatic pancreatic adenocarcinoma and umbilical cutaneous metastasis after receiving first-line chemotherapy. The diagnosis was established upon liver biopsy in July 2019, after the patient presented with a complaint of transfixing abdominal pain. The first-line treatment consisted of six cycles of modified FOLFIRINOX chemotherapy. However, in November 2019, computed tomography (CT) scan showed disease progression. Second-line treatment with gemcitabine (Gemzar®) led to a 16% decrease in target lesions. During the fourth cycle, three periumbilical indurated nodules appeared. After six cycles, skin infiltration had increased, and the patient reported his abdominal pain had intensified. Reassessment by CT scan showed an increase in both hepatic and peritoneal disease progression. Third-line treatment with FOLFIRI, started on April 15, 2020, could not control the disease, leading to greater induration and subcutaneous infiltration, which were responsible for the increased pain and ultimate death. Umbilical skin metastases are rare, and they are associated with advanced metastatic disease and a very poor prognosis. Cases reporting Sister Mary Joseph nodules are needed to better understand the conditions and mechanisms of their appearance and dissemination., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 by S. Karger AG, Basel.)

Published
2021
Full Text
View/download PDF

20. Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers.

Author

Bernadach M, Lapeyre M, Dillies AF, Miroir J, Casile M, Moreau J, Molnar I, Ginzac A, Pham-Dang N, Saroul N, Durando X, and Biau J

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols pharmacology, Cisplatin pharmacology, Cisplatin therapeutic use, Female, Fluorouracil pharmacology, Fluorouracil therapeutic use, Humans, Male, Middle Aged, Taxoids pharmacology, Taxoids therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Head and Neck Neoplasms drug therapy, Induction Chemotherapy methods
Abstract

Background: The rate of toxic deaths related to induction chemotherapy in the treatment of locally advanced head and neck cancers is unacceptable and calls into question this therapeutic strategy, which is however highly effective in terms of rate and speed of response. The purpose of the study was to investigate predictive factors of toxicity of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced head and neck cancers (LAHNC)., Methods: Between June 2009 and December 2017, 113 patients treated consecutively with TPF were included retrospectively. Patients were receiving induction chemotherapy for either an inoperable cancer or laryngeal preservation. For inoperable cancer, induction chemotherapy was proposed to patients presenting either a large tumor with strong symptoms (dyspnea, dysphagia, pain) or a tumor with rapid progression. Risk factors were chosen among the initial patient and tumour characteristics and chemotherapy modalities., Results: Eighty-nine patients (79%) were male; the median age was 58 years [32-71]. Sixty-nine (61%) patients were treated for inoperable cancer and 44 (39%) for laryngeal preservation. 45% had stage IVa cancer, 28% stage III and 25% stage IVb. Sixty percent of patients had a partial response after TPF, 22% had a complete response, 12% were stable, 5% were progressing, and 1% had a discordant response. Thirty-four patients (30%) received enteral feeding during induction chemotherapy with TPF. The possibility of oral feeding without a tube was predictive of a better response (p = 0.003). Seven (6%) patients died during TPF. There was an increased risk of death with preexisting liver dysfunction (liver dysmorphia on imaging or decrease prothrombin rate) (p = 0.032). There was an increased risk of grade ≥ 3 infection if an enteral feeding occurred during the period of induction chemotherapy (p = 0.03)., Conclusions: TPF induction chemotherapy had an 82% objective response rate with 6% toxic deaths. Nutritional status and the presence of hepatic dysfunction are significant risk factors to be taken into account in therapeutic decisions.

Published
2021
Full Text
View/download PDF

21. Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report.

Author

Wong-Chong J, Bernadach M, Ginzac A, Veyssière H, and Durando X

Abstract

Background: Thymic epithelial carcinomas are rare and have a poor prognosis. Treatment of thymic epithelial carcinoma is multimodal and includes surgery, post-operative radiation therapy, adjuvant and neoadjuvant chemotherapy, or exclusive chemotherapy based on disease resectability. However, there is currently no standard treatment regimen for metastatic and recurrent thymic carcinoma., Case Summary: A 45-year-old Caucasian male, with no past medical history, presented with hepatalgia and a cervical mass. A computed tomography (CT) scan showed multiple suspect lesions in the lungs, liver, and anterior mediastinum associated with mediastinal and cervical adenopathy. CT-guided percutaneous biopsies of the liver lesions and anterior mediastinal mass were performed, confirming the histopathology of thymic epithelial carcinoma. Management consisted of several chemotherapy regimens and radiation therapy, administered between April 2016 and December 2018. The patient achieved complete metabolic response. Fluorodeoxyglucose positron emission tomography/CT performed in June 2019 showed disease relapse, with reappearance of a large hypermetabolic hepatic mass and involvement of mediastinal and axillary lymph nodes. Intravenous pembrolizumab (200 mg, every 3 wk) was administered after two prior systemic therapies. The patient's response to treatment was last documented on March 5, 2020., Conclusion: Pembrolizumab was successful in treatment of a patient with programmed death-ligand 1-negative metastatic thymic carcinoma, pretreated with chemotherapy., Competing Interests: Conflict-of-interest statement: The authors declare having no conflicts of interest in relation to this case or its publication., (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.)

Published
2021
Full Text
View/download PDF

22. PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer.

Author

Lusho S, Durando X, Bidet Y, Molnar I, Kossai M, Bernadach M, Lacrampe N, Veyssiere H, Cavaille M, Gay-Bellile M, Radosevic-Robin N, and Abrial C

Subjects
Adolescent, Adult, Biomarkers, Tumor blood, Breast Neoplasms mortality, Female, Humans, Lymphocyte Count, Lymphocytes metabolism, Middle Aged, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local mortality, Platelet Count, Predictive Value of Tests, Prognosis, Triple Negative Breast Neoplasms mortality, Young Adult, Blood Platelets metabolism, Breast Neoplasms blood, Lymphocytes, Tumor-Infiltrating metabolism, Neutrophils metabolism, Triple Negative Breast Neoplasms blood
Abstract

Background: Triple negative breast cancer affects 10% to 20% of all women diagnosed with breast cancer. Due to its characteristics, treatment strategies are limited and metastatic recurrences are common in the first 5 years after treatment. However, not all patients affected by this disease develop metastases. Tumor-infiltrating lymphocytes have shown to be reliable predictive biomarkers of treatment response and metastatic recurrences. However, we need to develop simpler and faster ways to predict response to cytotoxic treatment and the possibility of eventual cancer relapse by identifying new biomarkers. Recently, new studies are emerging, suggesting a predictive role of circulating blood cells in different types of cancer. In this study, we will assess the correlation between tumor-infiltrating lymphocytes and different elements of the blood count in patients diagnosed with triple negative breast cancer., Methods: The main objective of this study is to evaluate the correlation between the peripheral neutrophil-to-lymphocyte ratio and the amount of tumor-infiltrating lymphocytes, assessed in triple negative breast cancer patients at diagnosis. Secondary objectives include evaluation of the correlation between tumor-infiltrating lymphocytes at diagnosis and the baseline absolute neutrophil, lymphocyte, and platelet counts, as well as the platelet-to-lymphocyte ratio. The triple negative breast cancer patients will be enrolled in the PERCEPTION trial during the first year after the treatment completion. Two supplementary blood tests, at 12 months after the end of treatment and at the time of the first metastatic recurrence, will be performed., Discussion: The discovery of new prognostic and predictive biomarkers is crucial for triple negative breast cancer. We set up the PERCEPTION clinical trial in order to evaluate certain blood counts as early biomarkers and to assess their correlation with tumor-infiltrating lymphocytes. Demonstration of comparative predictive and/or prognostic capacities of peripheral blood counts and tumor-infiltrating lymphocytes would allow introduction of the former as simple and cheap biomarkers in triple negative breast cancer patient management., Trial Registration: The PERCEPTION study has been registered in the French National Agency of Medical Security registry on the 2nd of July 2019 under the number 2019-A01861-56 and in the ClinicalTrials.org registry under the number NCT04068623.

Published
2020
Full Text
View/download PDF

23. XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer.

Author

Veyssière H, Passildas J, Ginzac A, Lusho S, Bidet Y, Molnar I, Bernadach M, Cavaille M, Radosevic-Robin N, and Durando X

Subjects
Female, Heterografts, Humans, Neoadjuvant Therapy, Prospective Studies, Breast Neoplasms surgery
Abstract

Introduction: Patient-derived xenografts (PDX) can be used to explore tumour pathophysiology and could be useful to better understand therapeutic response in breast cancer. PDX from mammary tumours are usually made from metastatic tumours. Thus, PDX from primary mammary tumours or after neoadjuvant treatment are still rare. This study aims to assess the feasibility to establish xenografts from tumour samples of patients with triple negative or luminal B breast cancer in neoadjuvant, adjuvant or metastatic setting. Methods: XENOBREAST is a single-centre and prospective study. This feasibility pilot trial aims to produce xenografts from tumour samples of patients with triple negative or luminal B breast cancer. Patient enrolment is expected to take 3 years: 85 patients will be enrolled and followed for 28 months. Additional blood samples will be taken as part of the study. Surgical specimens from post-NAC surgery, primary surgery or surgical excision of the metastases will be collected to establish PDX. Histomolecular characteristics of the established PDX will be investigated and compared with the initial histomolecular profile of the collected tumours to ensure that they are well-established. Ethics and dissemination: XENOBREAST belongs to category 2 interventional research on the human person. This study has been approved by the Sud Méditerranée IV - Montpellier ethics committee. It is conducted notably in accordance with the Declaration of Helsinki and General Data Protection Regulation (GDPR). Study data and findings will be published in peer-reviewed medical journals. We also plan to present the study and all data at national congresses and conferences. Registration: ClinicalTrials.gov ID NCT04133077; registered on October 21, 2019., Competing Interests: No competing interests were disclosed., (Copyright: © 2021 Veyssière H et al.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results